Therapeutic potential of surgery for metastatic colorectal cancer

Abstract

Evidence of the clinical benefit of surgery or metastasectomy for metastatic colorectal cancer to disease sites including the liver, lung, peritoneum, and pelvis as a potentially curative option is now available in the literature. The oncologic outcome of this treatment strategy achieves 5-year survival ranging between 20% and 50%. These survival gains have not been previously observed in the management of metastatic colorectal cancer. Treatment of potential surgical candidates requires a combined modality approach with systemic therapies to achieve macroscopic tumor removal and microscopic targeting of tumor deposits to achieve disease control. In nonsurgical candidates, systemic therapy, radiation therapy, and interventional oncology procedures may potentially facilitate sufficient disease downstaging for surgery. The purpose of this article is to provide a comprehensive review of the therapeutic advances in the surgical management of metastatic colorectal cancer.

Key Words::

• bevacizumab
• colorectal cancer
• irinotecan
• irinotecan
• liver metastases
• oxaliplatin
• pulmonary metastases
• rectal cancer

Declaration of interest: The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.